Prostate cancer is the fifth leading cause of cancer death worldwide and biomarkers with
improved specificity and sensitivity are in urgent need for precise prognosis and diagnose …

Prostate cancer (PCA) is a major health concern in current times. Ever since prostate
specific antigen (PSA) was introduced in clinical practice almost three decades ago, the …

Prostate cancer is among the most frequent cancers in men worldwide. Despite the fact that
multiple therapeutic alternatives are available for its treatment, it is often discovered in an …

Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The
discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and …

The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most
common noncutaneous cancer in American men, with an estimate of 192,280 new cases …

Simple Summary Prostate cancer is a heterogeneous disease and a major cause of cancer
deaths worldwide. The most widely used prostate cancer biomarker, prostate-specific …

Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide.
Although increased expression of prostate-specific antigen (PSA) is an effective indicator for …

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and
the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is …

Despite the advancements in innovation and usage of biomarkers in prostate cancer, there
exists tremendous potential in improving them to fulfil the unmet need that exists today …

The introduction of prostate‐specific antigen (PSA) has revolutionized the detection and
management of patients with prostate cancer. Despite this there has always been a concern …